Section Arrow
CABA.NASDAQ
- Cabaletta Bio
Quotes are at least 15-min delayed:2025/09/05 17:04 EDT
After Hours
Last
 1.69
-0.01 (-0.59%)
Bid
1.69
Ask
1.71
High 1.72 
Low 1.68 
Volume 12300 
Regular Hours
Last
 1.7
+0.16 (+10.39%)
Day High 
1.7165 
Prev. Close
1.54 
1-M High
1.8299 
Volume 
2.42M 
Bid
1.69
Ask
1.71
Day Low
1.56 
Open
1.57 
1-M Low
1.26 
Market Cap 
140.86M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.54 
20-SMA 1.54 
50-SMA 1.58 
52-W High 5.46 
52-W Low 0.9857 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.71/-1.80
Enterprise Value
146.48M
Balance Sheet
Book Value Per Share
1.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GNPXGenprex0.2295+0.0738+47.40%0.18PE
After Hours 0.1956 -0.0339 -14.77%
ADAPAdaptimmune Therapeutics plc0.041-0.01-19.61%-- 
After Hours 0.0422 +0.0012 +2.93%
NUVBNuvation Bio3.9+0.48+14.04%-- 
After Hours 3.89 -0.01 -0.26%
KLTOKlotho Neurosciences Inc0.4851-0.0099-2.00%-- 
After Hours 0.479 -0.0061 -1.26%
IOVAIovance Biotherapeutics2.49+0.29+13.18%-- 
After Hours 2.47 -0.02 -0.80%
Quotes are at least 15-min delayed:2025/09/05 17:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients withB cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies,or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.